English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
DNA damage, oncogene activation and chromatin
Share :
ECCO 15 - ESMO 34
20 - 24 Sep 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
29 Sep 2009
Views:
14261
Rating:
Save
Rate video
Dr Fabrizio d'Adda di Fagagna - Principal Investigator, IFOM-IEO, Milan, Italy
Dr Fabrizio d'Adda di Fagagna, Principal Investigator, IFOM-IEO, Milan, Italy
Categories:
Biology
Cytotoxics
Related Videos
Biomarkers, Predictive and Prognostic Factors of Resistance to Immunotherapy
Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...
12 Jul 2024
Hormonal Receptor Positive Breast Cancer Adjuvant and Metastatic Indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
12 Jul 2024
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2...
Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy
9 Jul 2024
Administering systemic chemotherapy improves survival for patients with...
Dr Giacomo Bregni - Francis Crick Institute, London, England
9 Jul 2024
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...
Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany
27 Jun 2024
ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
26 Jun 2024
ATRA-ATO regimen with idarubicin could become the new standard of care in high...
Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany
25 Jun 2024
Ponatinib is better than imatinib for frontline treatment of newly diagnosed...
Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
24 Jun 2024
Isatuximab in combination with pomalidomide and dexamethasone shows promising...
Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece
19 Jun 2024
More from
e
cancer